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Abstract
Background: Duchenne muscular dystrophy (DMD) is a lethal, progressive muscle wasting disease caused by a loss of
sarcolemmal bound dystrophin, which results in the death of the muscle fibers leading to the gradual depletion of skeletal
muscle. There is significant evidence demonstrating that increasing levels of the dystrophin-related protein, utrophin, in
mouse models results in sarcolemmal bound utrophin and prevents the muscular dystrophy pathology. The aim of this
work was to develop a small molecule which increases the levels of utrophin in muscle and thus has therapeutic potential.
Methodology and Principal Findings: We describe the in vivo activity of SMT C1100; the first orally bioavailable small
molecule utrophin upregulator. Once-a-day daily-dosing with SMT C1100 reduces a number of the pathological effects of
dystrophin deficiency. Treatment results in reduced pathology, better muscle physiology leading to an increase in overall
strength, and an ability to resist fatigue after forced exercise; a surrogate for the six minute walk test currently
recommended as the pivotal outcome measure in human trials for DMD.
Conclusions and Significance: This study demonstrates proof-of-principle for the use of in vitro screening methods in
allowing identification of pharmacological agents for utrophin transcriptional upregulation. The best compound identified,
SMT C1100, demonstrated significant disease modifying effects in DMD models. Our data warrant the full evaluation of this
compound in clinical trials in DMD patients.
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Introduction
Duchenne muscular dystrophy (DMD) is a lethal X-linked
recessive muscle wasting disease caused by mutations in the
dystrophin gene (for review see [1]). Affected boys are ambulatory
until about 12 years of age but often live into their twenties with
recent improvements in respiratory support. Many boys show an
abnormal ECG in the late stages of the diseases and cardiomy-
opathy is also a general feature. The milder form of the disease
known as Becker muscular dystrophy (BMD) is also characterized
by cardiac defects despite BMD patients often being ambulant in
their 50s and 60s. Thus, any therapy for the disease would need
not only to target skeletal, but also cardiac muscle.
Currently there is no effective treatment for DMD. Various
strategies developed to alleviate the symptoms include steroid
treatment, anti-inflammatory agents, and growth hormone and
myostatin inhibitors (for review see [2]). More recently, genetic
approaches have been tested in DMD patient trials. In particular,
readthrough of stop codons has been attempted in the 10–15% of
patients that have mutations resulting in premature stop codons
resulting in dystrophin deficiency. An orally delivered small
molecule, Ataluren, recently entered a phase IIb trial. The six
minute walk distance test [3] (6MWD) was used as the primary
efficacy endpoint as the ability to walk further after treatment is
considered by the regulatory authorities as a major improvement
in the quality of life for these patients. Unfortunately, after
conclusion of the trial, no statistically significant increase in the
distance travelled using the 6MWD was reported. Skipping of
exon 51, which targets up to 13% of patients, represents the
monoskipping therapy which would be applicable to the largest
proportion of DMD patients. Antisense molecules, delivered either
intravenously or sub-cutaneously, have shown some restoration of
dystrophin to a variable degree in patients [4,5]. Next generation
trials are planned with constructs which increase the efficiency of
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6delivery of the antisense oligonucleotides. The efficacy of this
approach was demonstrated using the dystrophin/utrophin knock-
out mouse, where restoration of muscle function was demonstrated
[6]. To treat more patients, different antisense sequences will need
to be developed to target other exons and the regulatory
authorities may treat each of these new constructs as a new drug.
The ideal scenario would be to develop multi-exon skipping [7]
but this may only be achieved using AAV delivery which faces
immunological problems.
We have taken an alternative pharmacological approach to
DMD by developing an orally bioavailable small molecule which
should be appropriate to treat all patients irrespective of their
mutation and target both skeletal and cardiac muscle. Building on
our work in the mdx mouse, which demonstrated that the loss of
dystrophin could be compensated for by increasing the levels of
the dystrophin-related protein, utrophin, we have developed novel
small molecules which can transcriptionally upregulate the
utrophin gene. The demonstration that increased utrophin can
reduce the muscular dystrophy in the mdx mouse has been
confirmed by others [8–11]. Our early data from the mdx mouse
suggested that increasing the levels of utrophin over two-fold
would be of great benefit [12].
SMT C1100 was the final product of an exhaustive chemical
screening and optimisation campaign. In this paper we present
evidence confirming an overall two-fold increase in both utrophin
RNA and protein resulting in a significant reduction in dystrophic
symptoms and increased muscle function in dystrophin-deficient
mdx mice. This was a comprehensive study looking at the
beneficial effects of daily dosing of SMT C1100 in both sedentary
mdx and the more severely affected forced exercise model. If the
results obtained here using SMT C1100 translated across to DMD
patients then undoubtedly this would be a disease modifying
therapy for DMD.
Methods
Ethics Statement
All animal procedures were performed in accordance with UK
Home Office regulations or in accordance with the Italian
Guidelines for the use of laboratory animals, which conform with
the European Community Directive published in 1986 (86/609/
EEC). The work performed in Oxford was performed under
certificate of designation number 30/2306 and project license
number 30/2652 following approval by the University of Oxford
Departments of Physiology, Anatomy & Genetics and Experi-
mental Psychology Joint Departmental Ethics Review Committee.
The work performed by Covance Laboratories Ltd. was
performed under certificate of designation number 50/8504 and
project license number 60/3774 following approval by the
Covance Ethical Review Process. The work in Bari was approved
by the central review board under the Italian Minister of Health
which authorizes that all animal studies conform to the ethical
requirement and current law.
Generation of a utrophin promoter screening cell line
Murine H2K cells [13] were transfected with 8.4 kb of the
human utrophin promoter including the first untranslated exon
linked to a luciferase reporter gene and stable lines generated for
screening (H2K-mdx utrnA-luc).
Cell culture
The H2K-mdx utrnA-luc cells were maintained in DMEM
(Invitrogen) supplemented with 20% Fetal Bovine Serum Gold
(PAA), 5% CEE (SLI), 2 mM L-Glutamine (Invitrogen), 1%
Penicillin Streptomycin (Invitrogen) and 2 mg/500 ml Mouse
Interferon-c (Roche). Cells were maintained at 10% CO2 at
33uC. Normal human skeletal muscle cells (SkMc) were sourced
from TCS cell works. Passaging was undertaken according to the
supplier’s instructions including the use of specialist culture media.
Cells were maintained at 5% CO2 at 37uC.
In vitro assays
For luciferase assays plates were seeded with H2K-mdx utrnA-
luc at 5000 cells per well. These were incubated in 10% CO2 and
33uC for 24 h prior to dosing.
All compounds were supplied as a 10 mM solution in dimethyl
sulfoxide (DMSO). Cells were treated compounds dissolved in a
final concentration of 0.3% DMSO. Assays were performed in
triplicate and the compounds were dosed for 48 h. Luciferase
levels were measured using the Steady-Glo Luciferase kit
(Promega) and the plates were then read using a FLUOstar
Optima plate reader (BMG Labtech). The means from the
biological triplicates were used in a 4 Parameter Logistic Model to
generate an EC50 and Hill slope. The software used to calculate
this was XLfit version 4.2.2.
Sedentary mice and drug treatment
Three week-old male mdx (C57BL/10ScSn-Dmd
mdx/J; Charles
River Laboratories, MA, USA) littermates were randomly split
between 2 groups and treated with SMT C1100 (50 mg/kg) or
vehicle only (phosphate buffered saline (PBS), 0.1% Tween-20, 5%
DMSO) via daily i.p. injection for four weeks. At the end of the
drug treatment period mice were sacrificed by CO2 asphyxiation
in accordance with Schedule I of the UK Animals (Scientific
Procedures) Act 1986. C57BL/6 contractile properties were
measured in EDL muscle dissected from eight week old untreated
mice obtained at 4 week of age from Harlan (n=5). All animal
procedures were performed in accordance with UK Home Office
regulations. In all other experiments described using the sedentary
mdx mice dosing was by the oral gavage using a canula to deliver
SMTC1100 or vehicle only on a daily basis for 28 days. At the end
of this period the mice were sacrificed and muscle and blood
samples were taken. Quantification of muscle and plasma levels of
SMT C1100 was performed using CD1 mice.
Exercised mice, treadmill running and drug treatment
Most of the experimental procedures conform to the standard
operating procedures for pre-clinical tests using mdx mice available
at http://www.treat-nmd.eu/research/preclinical/SOPs/.
A total of 24 mdx male mice of 4–5 weeks of age (Charles River-
Italy), and homogeneous for body weight, underwent a 30 min
running regime on an horizontal treadmill (Columbus Instru-
ments) at 12 m/min, twice a week (keeping a constant interval of
2–3 days between each trial), for 4–6 weeks, according to a
standard protocol [13,14]. Experimental groups were treated as
follows: vehicle only (n=7), SMT C1100 (50 mg/kg; n=6), a-
methyl prednisolone (PDN; 1 mg/kg; n=5) and combination of
SMT C1100 (50 mg/kg) and PDN (1 mg/kg) (n=6). Age and
gender-matched wild type C57/BL10ScSn) or non-exercised mdx
mice were also used for specific experimental purposes, as
indicated in the text. The dose of PDN has been chosen based
on our previous studies [14]. The treatment started one day before
the beginning of the exercise protocol, and continued until the day
of sacrifice. SMT C1100 and the combination of PDN+SMT
C1100 were dissolved in 5% DMSO, 0.1% Tween-20 in PBS,
whilst PDN was dissolved in sterile water. Drugs were formulated
for i.p. injection so that the correct dose was administered in
0.1 ml/10 g. Body weight was assessed weekly, as was fore-limb
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USA) [14,15]. An exercise resistance test, consisting of horizontal
running for 5 min at 5 m/min, then increasing the speed of 1 m/
min each minute, was performed on week 0 and after four and five
weeks of treatment. The total distance run by each mouse until
exhaustion was measured [15]. At the end of the 5
th week of
exercise/treatment the ex vivo experiments were also started. To
this aim mice were deeply anesthetized and sacrificed using 1.2 g/
kg urethane (i.p.) in accordance with the Italian Guidelines for the
use of laboratory animals, which conform with the European
Community Directive published in 1986 (86/609/EEC).
Muscle mechanics/electrophysiology
Muscle mechanics were conducted on the extensor digitorum
longus (EDL) muscle as previously described [6]. EDL muscles
were removed and rapidly placed in the recording chamber for the
electrophysiological or isometric recordings. In the recording
chambers EDL muscles were bathed at 3061uC in the following
normal physiological solution: NaCl 148 mM, KCl 4.5 mM,
CaCl2 2.0 mM, MgCl2 1.0 mM, NaHCO3 12.0 mM, NaH2PO4
0.44 mM, glucose 5.55 mM, and continuously gassed with 95%
O2 and 5% CO2 (pH 7.2–7.4). The mechanical threshold (MT)
was determined in EDL muscle fibres by the two microelectrode
‘‘point’’ voltage clamp method, described previously [13,14]. In
brief, depolarizing command pulses of variable duration (from 500
to 5 ms at 0.3 Hz) were progressively increased in amplitude from
the holding potential (H) of 290 mV until a visible fiber
contraction. The mean threshold membrane potential values of
individual myofibers (V, in mV) at various pulse durations (t, in
ms) allowed the construction of a ‘‘strength-duration’’ curve. The
rheobase voltage (R, in mV) was obtained by a non-linear least
square algorithm using a previously described equation [14,15].
Protein analyses
A human DMD cell line with a deletion of exons 49 and 50
(generously provided by Vincent Mouly, Paris) was seeded in 6 cm
dishes in DMEM (Invitrogen), Medium 199 (20%; Sigma-Aldrich),
Fetal Calf Serum (20%; Invitrogen), glutamine and penicillin/
streptomycin (Invitrogen) 24 h prior to drug treatment. After three
days of drug treatment cells were lysed for 20 min at 4uC in Tris
pH6.8 (75 mM), SDS (3.8%), Urea (4 M), glycerol (20%)
supplemented with protease inhibitors (1:100; Sigma-Aldrich).
Soluble protein was purified at 80006g for 20 min at 4uC and
30 ml was size fractionated by 5% Tris-HCL SDS-PAGE gel
electrophoresis and transferred to a PVDF membrane (GE
Healthcare). Soluble protein was prepared from muscle samples
snap frozen in liquid nitrogen and stored at 280uC until use for
biochemical analysis. For western blotting, protein was crushed
with a pestle in a liquid nitrogen-cooled mortar, solubilised in
50 volumes of single-section western blot lysis buffer [16],
vortexed, briefly homogenised and sonicated, heated to 94uC for
4 minutes and centrifuged for 3 min at 15 0006g to remove
insoluble matter. For western blotting, 50 ml soluble protein
extract was separated by 5% Tris-HCL SDS-PAGE gel electro-
phoresis and transferred onto PVDF (GE Healthcare). Utrophin
protein was detected using MANCHO 3 antibody (1:100; kind gift
from G.E. Morris, Oswestry, UK) and ECL HRP-conjugated anti-
mouse antibody (GE Healthcare). Equal protein loading was
corrected by detection of a-actinin (1:200, N-19; Santa Cruz
Biotechnology, Inc.) and a HRP-conjugated anti-goat antibody
(Sigma). Blots were developed using ECL reagent (GE Health-
care), Densitometry was performed using the freely available web
version of Image J (rsbweb.nih.gov/ij/). Immunohistochemistry
was carried out as previously described [17].
RNA analyses
For quantitative real time RT-PCR SkMC cells were seeded in six
well plates at 25000 cells per well in 3 ml of appropriate media and
incubated for 24 h prior to dosing. Compounds were dosed in a final
concentration of 1% DMSO for 72 h. RNA was extracted from tissue
using a QIAGEN RNeasyH Plus kit (Qiagen) and QiaShredder
(Qiagen), using the manufacturer’s instructions. The High-Capacity
cDNA Reverse Transcriptase Kit (Applied Biosystems) was used
according to manufacturer’s instructions. Real-time PCR was per-
formed according to the DDCT method [18]. The 7300 Real-Time
PCR System from Applied Biosystems was used for this assay along
with the 7300 System SDS software with the SDS Relative Quanti-
fication Study Plug in. Data was analysed using the 7300 System SDS
software with the SDS Relative Quantification Study Plug in.
Blood analyses
Measurements of SMT C1100 plasma concentrations were
obtained following RO (retro-orbital) blood sampling on day 1,
24 h after oral dosing with SMT C1100 (50 mg/kg) or vehicle
only (0.1% PBS-Tween-20/5% DMSO). Further samples were
taken at day 15 and day 28 after the start of dosing.
Blood was collected with non-heparinized hematocrit tubes into
serum microtainer tubes and centrifuged for 12 min at
12,000 rpm at 4uC. Serum was stored at 280uC prior to analysis
using the CK (NAC) reagent kit in conjunction with the AU 400
Clinical Chemistry analyser (Olympus UK Ltd).
Histological analyses
After 28 days of dosing muscle samples were taken for
histopathology and processed by Premier Laboratory LLC
(Colorado, U.S.A.). Samples were received in 10% neutral buffered
formalin, processed into paraffin, and 5 mm sections and stained for
Hematoxylin and Eosin (H&E) and Masson’s Trichrome (tibialis
anterior, extensor digitorum longus, soleus, and diaphragm). Both
the H&E and Masson’s Trichrome stained slides were submitted
blind to a Board Certified Veterinary Pathologist at Premier
Laboratory LLC and scored for the presence of inflammation and
fibrosis. A total of five sections from each muscle were analysed.
The muscle fibres were scored according to the following criteria:
Inflammation:
0=none to minimal - No inflammation within the muscle
bundles or inter-bundle connective tissue; occasional
mononuclear inflammatory cells may be present but no
obvious aggregations.
1=mild - Occasional mononuclear inflammatory cells
in the inter-bundle connective tissue with focal aggre-
gations of mononuclear inflammatory cells.
2=moderate - Multiple foci of mononuclear inflamma-
tory cell infiltration in the inter-bundle connective tissue;
occasional mononuclear inflammatory cells between
individual muscle fibres.
3=severe - Multiple large foci of mononuclear inflamma-
tory cell infiltration in the inter-bundle connective tissue
extending into the intra-bundle connective tissue with
expansion of the inter-bundle and intra-bundle space.
Fibrosis:
0=none to minimal - No fibrosis in the muscle bundles
or inter-bundle connective tissue; mild expansion of the
inter-bundle connective tissue may be present focally.
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tive tissue; mild focal expansion of the intra-bundle
space may be present.
2=moderate - Multiple foci of expansion of the
connective tissue component in the inter-bundle area;
focal intra-bundle increases in connective tissue between
individual muscle fibres.
3=severe - Multiple large foci of connective tissue in the
inter-bundle region extending into the intra-bundle
connective tissue with expansion of the inter-bundle
and intra-bundle space.
In addition two 42-bit color images were captured with a Zeiss
AxioCam HR digital camera on a Zeiss Axioskop 2 microscope
utilizing AxioVision 4.4 software (Zeiss) of each muscle on the
H&E stained slides. Once the images were captured they were
white balanced in Adobe Photoshop (Adobe). The proportion of
centrally nucleated fibers was determined by analyzing the images
and counting the number of centrally located nuclei; a total of two
hundred cells per muscle were evaluated. Students’ two-tailed t-
test was used to compare the groups with significance set at
p,0.05.
Statistical Analyses
Significance was calculated using the Student’s t test with a two-
tailed distribution assuming unequal sample variance. Multiple
statistical comparisons between groups, was performed by one-way
ANOVA, with Bonferroni’s t test post-hoc correction for allowing
a better evaluation of intra- and inter-group variability and
avoiding false positive.
Results
In vitro upregulation of utrophin
SMT C1100 was identified from an iterative analoging
approach from initial hits identified using a human muscle specific
utrophin A promoter cell-based assay. Myoblasts (mdx) were cloned
from H-2K-tsA586mdx with an IFN/tsSV40 T-Ag transgene in
order to control proliferation and fusion [13]. The screening line
named H2K-mdx utrnA-luc contains a stably integrated reporter
consisting of 8.4 kb of the human utrophin promoter linked to a
luciferase reporter gene. The region of the utrophin promoter
contained all the motifs known to control utrophin expression
[19,20]. This high throughput screening assay identified a number
of luciferase-inducing compounds that also have the ability to
increase the transcription of the endogenous mouse UTRN, thus
identifying compounds with both human and mouse activity
eventually leading to the final optimized compound, SMT C1100
whose chemical structure is shown in Fig. 1A.
SMT C1100 shows a maximal increase of four to five-fold
compared to vehicle with an EC50 of 0.4 mM (Fig. 1A). In vitro
dosing of human myoblasts with SMT C1100 leads to a 25%
increase in utrophin mRNA (Fig. 1B) when compared to vehicle-
only dosing after three days of treatment. Treatment of human
Figure 1. In vitro activity of SMT C1100. (A) SMT C1100 dose
response in murine H2k-mdx utrnA-luc cells expressing the human
utrophin promoter linked to a luciferase reporter gene. Cells were
t r e a t e dw i t hc o m p o u n df o r4 8 hi ns t a n d a r dg r o w t hm e d i u m
containing 0.3% DMSO. The chart shows relative luminescence (RLU)
in relation to five different doses of SMT C1100. A Four Parameter
Logistic Model was used to generate an EC50. Points represent a mean
6S.E. of three experiments and are typical of the results for all batches
of SMTC1100. The structure for SMTC1100 is shown; (B) SMT C1100
significantly increased mRNA copy number of the utrophin transcript in
SkMC cells. In this assay Gene Expression Assay 4326315 was used for b-
actin detection and Gene Expression Assay Hu01125984_m1 was used
for utrophin transcript detection (both Applied Biosystems). Cells were
exposed to SMT C1100 in standard media with 1% DMSO (vehicle) for
72 hours with six biological replicates. *p=0.01 relative to vehicle only;
(C) Utrophin protein levels in human DMD cell line treated with SMT
C1100 (1 mM) or vehicle (0.1% DMSO). Blots were stained with anti-
utrophin (MANCHO3; 1:100) and ECL HRP-conjugated anti-mouse
antibody (GE Healthcare). Bands were quantified using Image J and
arbitrary units represent utrophin levels corrected for equal loading by
a-actinin immunostaining. Results represent a mean 6 S.E based on
n=3. {p=0.00683; 1p,0.001; #p,0.005 relative to vehicle-treated
cells.
doi:10.1371/journal.pone.0019189.g001
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protein levels at an optimal concentration of 0.3 mM after 3 days
of treatment (Fig. 1C).
Plasma levels of SMT C1100
Significant plasma (Fig. 2A) and muscle (Fig. 2B) levels of
compound were achieved for several hours following oral
administration of SMT C1100 (50 mg/kg). From the EC50 data
(Fig. 1A), taken together with the levels of utrophin upregulation
achieved at various drug concentrations in both DMD and normal
myoblasts, we can estimate that the effective concentration
required for efficacy would be in the order of 0.5–1 mM. This
means that therapeutic levels are achieved in muscle for at least
eight hours following dosing.
Toxicological evaluation of SMT C1100
In order to confirm that SMT C1100 had no obvious off target
toxicological liabilities mice were dosed with high levels of
compound. Overall no toxicologically significant changes in
clinical condition, body weight, food consumption, haematology
or clinical chemistry parameters were seen during the study. There
were no microscopic findings within the comprehensive set of
tissues analysed due to effects of SMT C1100. Conclusion from
Covance Laboratories Ltd. confirmed that the study did not
identify any toxicity that was attributable to dosing with
SMTC1100. Based on the conditions of this study, it was
considered that no toxicity was determined for SMT C1100
administered by oral gavage to the mouse up to dose levels of
2000 mg/kg/day for 28 days. This information was a key
component of the toxicology assessment which led to a successful
clinical trial application and testing in healthy volunteers. This was
only one component of a significant package of safety evaluation
performed on SMT C1100.
In vivo upregulation of utrophin
To confirm the in vivo activity of SMT C1100, the dystrophin-
deficient mdx mouse was used to monitor any changes in the
dystrophic phenotype after chronic dosing for several weeks. To
confirm increases in utrophin expression after repeated daily
dosing with SMT C1100, muscle samples were taken for RNA and
protein analysis. Fig. 3A demonstrates a two-fold increase in
utrophin mRNA as determined by quantitative PCR from mdx
mice dosed daily with SMT C1100 for 28 days compared to
vehicle only. Fig. 3B demonstrates significant increases in utrophin
protein quantified from western blots of heart; a muscle
notoriously difficult to target with systemic administration of
putative DMD therapeutics, and diaphragm; the skeletal muscle
most affected in sedentary mdx mice. Fig. 3C illustrates a
qualitative increase in sarcolemmal-bound utrophin in the tibialis
anterior (TA) and EDL muscles after repeat dosing with SMT
C1100 following muscle sectioning. A similar result has been
observed in both diaphragm and hind limb muscles of forced
exercise-treated mdx mice (data not shown), suggesting no impact
of work load on drug action. This data confirms SMT C1100
drives increased utrophin transcriptional expression in vivo and,
more importantly, demonstrates increased utrophin staining at the
required site of action - the sarcolemma - and independently from
muscle work load.
Benefits of daily dosing of sedentary mdx mice with SMT
C1100
In the case of the sedentary mdx mouse, there is a significant
triggering of muscle degeneration at around 4 weeks which
continues for a further 4 weeks where limb muscles then appear to
reach stasis and levels of regeneration remain stable. One muscle
where continued development of necrosis is seen is the diaphragm
muscle. The dosing schedule for SMT C1100-treated mice was a
single daily administration from day 21 for a further 28 days. This
period of dosing encompassed the necrotic degenerative phase
resulting from dystrophin deficiency.
The hypothesis to protect myofibres from damage in the
absence of dystrophin is that utrophin, if continually localised to
the sarcolemma, will replace dystrophin function. If dystrophin
negative fibres are protected from damage for longer by the
continued presence of utrophin then the catastrophic secondary
effects of regeneration, fibrosis and inflammation should be
reduced and muscle should be able to function for longer. All of
these endpoints are significantly improved in mdx dosed daily with
SMT C1100 for several weeks compared to mdx dosed with
vehicle-only. SMT C1100 addresses the primary cause of fibre loss
by protecting the sarcolemma from damage as exemplified by
increased resistance to eccentric contractions (Fig. 4A) and a
reduction in serum creatine kinase levels (Fig. 4B). At the point
where the muscle necrosis is at a maximum, SMT C1100 reduces
the release of CK into the plasma by 75% compared to vehicle
(Fig. 4B; 15 d after the start of dosing). When degeneration has
stabilised there is still significant benefit seen as evidenced by
continued lower levels of CK (Fig. 4B, 28 d after start of dosing).
This data also demonstrates that beneficial effects of SMT C1100
driven utrophin upregulation must occur within a few days after
the start of dosing.
The resultant protection of dystrophin-deficient fibres by
continued expression of utrophin resulted in a reduction in the
Figure 2. Plasma levels of SMT C1100 in the mouse. (A) SMT
C1100 plasma levels were assessed over a 24 h period after oral gavage
or i.p. delivery of 50 mg/kg of the compound into wild type CD1 mice.
At set time points after administration groups of three animals were
taken for blood samples at the times stated in the figure. (B) Thigh and
diaphragm samples from CD1 dosed orally with 50 mg/kg were
quantified for the presence of SMT C1100.
doi:10.1371/journal.pone.0019189.g002
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dosed with SMT C1100. This is demonstrated by a significant
reduction in the numbers of fibres with centrally localized nuclei,
as fibres with peripheral nuclei are thought to be more mature in
development and therefore to have been a component of the
muscle for longer (Fig. 4C). Significant reduction in centrally
nucleated fibres is seen in the skeletal muscles examined including
the diaphragm; a more severely affected mdx muscle which better
mimics the more severe pathology of a DMD patient.
As the cycle of fibre degeneration and regeneration is being
slowed by continued utrophin expression in SMT C1100-dosed
mdx then the cytoplasmic signals to engage in muscle repair
responses such as inflammation and fibrosis are reduced. In
normal muscle this inflammatory protection response is dampened
down as the proliferation of resident satellite cells fuse and
reconnects the broken fibres. However, with the constant
degeneration, these protection signals are not switched off,
resulting in the continued influx of inflammatory cells and
fibroblasts, leading to an increasing cascade of further fibre
damage and loss of muscle ‘‘space’’ by fibrotic plaques. Treatment
with SMT C1100 significantly reduces this damage by virtue of
the reduced fibre regeneration. Blinded analysis by a board-
certified veterinary pathologist of muscle sections from mdx mice
dosed with either vehicle or SMTC1100 demonstrated a
significant reduction in both inflammation and fibrosis. Whole
muscle sections were rated with a pathology score on a scale from
normal (0) – mild (1) – moderate (2) – severe (3). Pooled averages
of total scoring from the TA, EDL and soleus are shown (Fig. 5A).
A qualitative example of the extent of inflammation from a SMT
C1100-dosed EDL or vehicle dosed EDL (Fig. 5B) is shown where
the SMT C1100 section was scored as mild (occasional
mononuclear inflammatory cells in the inter-bundle connective
tissue with focal aggregations of mononuclear inflammatory cells)
and the mdx as moderate (multiple foci of mononuclear
inflammatory cell infiltration in the inter-bundle connective tissue;
occasional mononuclear inflammatory cells between individual
muscle fibres). This data confirms the concept of reduced fibre
damage due to utrophin localization leading to reduced inflam-
mation and fibrosis.
Benefits of daily dosing of forced exercise mdx mice with
SMT C1100
A forced exercise regime of chronic exercise was used as a
strategy to worsen the murine pathology [14,21]. Five week old
mdx mice underwent forced treadmill exercise twice a week and the
effects of daily SMT C1100 treatment under this exercise regime
were then evaluated.
This exercise protocol significantly worsens in vivo parameters
readily evaluated by non-invasive approaches, such as fore limb
grip and endurance tests. In particular, the exercise protocol
induced the typical decrease of fore limb force in vivo over time; a
reduction which is seldom observed in sedentary mdx. SMT
C1100-treated mdx showed a significant protection against
exercise-induced fore limb weakness, as demonstrated by both
the maximal strength achieved and the increase in strength after
four weeks of dosing (Fig. 6A, B). After four weeks of dosing both
Figure 3. Effect of SMT C1100 on in vivo utrophin levels in the
mdx mouse. (A) Two-fold increase in utrophin mRNA following daily
oral administration of mdx mice with SMT C1100 (50 mg/kg/day) or
vehicle only (PBS-Tween-20 (0.1%)/5% DMSO) from three weeks of age
for four weeks. Results represent the mean 6 S.E from six mice per
treatment group and are corrected for b-actin. *p=0.019; (B) Utrophin
protein levels in heart and diaphragm following treatment of mdx mice
as described in (A) above. Blots were stained with anti-utrophin
(MANCHO3; 1:100) and ECL HRP-conjugated anti-mouse antibody (GE
Healthcare). Bands were quantified using Image J and arbitrary units
represent utrophin levels corrected for equal loading by a-actinin
immunostaining. Results represent a mean 6S.E from eight mice per
treatment group except for heart vehicle only which is based on n=7.
*p,0.01; #p,0.05; (C) Immunohistochemical staining of EDL and TA
muscle sections (10 mm; 206 magnification) were prepared from mdx
mice treated as in (A). Sections were stained with anti-utrophin
polyclonal antibody URD40 (1:100) and fluorescein isothiocyanate-
conjugated anti-rabbit secondary antibody (1:1000).
doi:10.1371/journal.pone.0019189.g003
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observed in sedentary mdx and wild type mice.
Data with direct relevance to DMD treatment was generated
using a fatigue assessment of the mice which underwent forced
exercise. Fatigue was assessed in an acute endurance test and
estimated as the maximal distance run before exhaustion.
Sedentary mdx mice, although run for a shorter distance than
wild type [14], maintain the same exercise performance over time,
whilst the exercised mdx demonstrate a dramatic increase in
fatigability between the start and the fourth and fifth week of
training (Fig. 6C). A partial restoration of the resistance to fatigue
was observed in SMT C1100-dosed mice, with an increase in
distance travelled of around 50% compared to vehicle only after 5
weeks of dosing. Interestingly, this effect was similar to that
observed in the exercised mdx mice treated with PDN; which is
currently the gold standard in clinical treatment for Duchenne
patients. Significant synergy was observed when SMT C1100 was
co-administered with PDN for five weeks. The forced exercise mdx
were completely resistant to fatigue and were able to continue
running as far as the sedentary mdx (Fig. 6C). This equated to an
increase in distance travelled of around 350% compared to the
vehicle-treated forced exercise mdx.
Ex vivo analysis on isolated muscles from forced exercise mdx
mice demonstrated that SMT C1100 exerted a significant
amelioration of calcium-dependent functional parameters. These
are typically modified in mdx muscles due to the altered calcium
homeostasis, which in turn is believed to drive the rate of
Figure 5. Reduction in secondary pathological features. (A) Data
demonstrates the reduction in overall skeletal muscle inflammation and
fibrosis from mdx treated with SMT C1100 compared to vehicle only.
SMT C1100 (50 mg/kg) or vehicle was delivered daily by oral gavage to
groups of six mdx mice aged around 17 d for a total of 28 days. The TA,
EDL, soleus, and diaphragm were removed and five sections from each
muscle were stained and analysed blind by a board-certified veterinary
pathologist for evidence of inflammation and fibrosis using a standard
pathology scoring method described in the methods section. Scoring
(0–3) was made for each section from each muscle then averaged for all
muscles to give an overall assessment of improvement in the
pathological effects of dystrophin deficiency; (B) Qualitative assessment
of EDL muscle from SMT C1100-dosed mdx scored as 1=mild -
occasional mononuclear inflammatory cells in the inter-bundle connec-
tive tissue with focal aggregations of mononuclear inflammatory cells.
The arrows mark foci of inflammation. Qualitative assessment of EDL
dosed with vehicle and scored as 2=moderate - multiple foci of
mononuclear inflammatory cell infiltration in the inter-bundle connec-
tive tissue; occasional mononuclear inflammatory cells between
individual muscle fibres.
doi:10.1371/journal.pone.0019189.g005
Figure 4. Ex vivo analysis of SMT C1100 activity in the mdx
mouse. (A) mdx mice were treated with SMT C1100 (50 mg/kg/day) or
vehicle only (0.1% Tween-20/5% DMSO in PBS) via daily i.p. injection
from two weeks of age for four weeks. Whilst contracting tetanically,
EDL muscles were stretched at 15% of their fibre length. The difference
in force produced between the first and fifth stretch is represented as
an indicator of the resistance of the muscle to stretch-induced damage.
*p,0.05; **p,1.0610
25; (B) levels of serum creatine kinase following
oral gavage of mdx mice with 50 mg/kg SMT C1100 or vehicle from
three weeks of age for four weeks (C) Muscles from the dosing
described in (B) were processed to assess the percentage of centrally
nucleated fibres *p,0.01; (C)***p=0.0001; **p=0.005; *p=0.003.
doi:10.1371/journal.pone.0019189.g004
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strength-duration curve describing the mechanical threshold was
significantly shifted toward the more positive membrane potential
values and almost overlapped with that observed in wildtype
myofibres (Fig. 7A). The rheobase value of SMT C1100-treated
muscles approached the wild type value (269.360.4 mV), and
was approximately 5 mV less negative than that of non-treated
exercised group (270.561.2 mV vs. 27561.5 mV: p,0.05 by
Student’s t test). Interestingly, this parameter is not ameliorated by
a partial increase in dystrophin expression by gentamicin
treatment [21]. Similarly, the ratio between twitch and tetanic
tension was significantly reduced in SMT C1100-treated exercised
mdx EDL muscles with respect to untreated counterparts, again
demonstrating that SMT C1100 treatment generates similar
values to those typically found in wild type EDL muscle (Fig. 7B).
The amelioration of calcium-dependent parameters was paralleled
by a partial, although significant, 18% decrease in the cytosolic
Ca
2+ level, as determined by fura-2 microspectrofluorimetry [14]
(data not shown), thus corroborating that the sarcolemmal bound
utrophin stimulated by SMT C1100 treatment can improve
calcium-mediate mechanotransduction signalling.
Discussion
This manuscript illustrates the effectiveness of dosing a well-
established mouse model of DMD with a novel oral utrophin
upregulator for several weeks. SMT C1100 induces increased
levels of utrophin RNA in human muscle cells and significantly
reduces dystrophin-deficient muscle pathology to such an extent
that significant benefit on whole body strength and endurance is
observed. Currently PDN and deflazacort are the only drugs
approved by the regulatory authorities for the treatment of DMD.
We believe that fatigue testing of mdx after a regime of forced
exercise is a good surrogate for the primary clinical endpoint
which will be used in DMD trials, i.e. in the 6MWD. Dosing with
SMT C1100 alone demonstrated significant benefit in this
surrogate model, and the 50% increase in the distance walked
would have achieved the required efficacy endpoint if translated
over to the 6MWD in DMD trials. Combining doses of SMT
C1100 and PDN for several weeks completely prevented fatigue in
this model. Thus, the combination of the two drugs with presumed
different modes of action protect the muscle from fatiguing with
exercise, thereby allowing for significantly increased ambulation.
High levels of long term steroid use have unwanted side effects,
however a steroid sparing therapy (either reducing dose or
frequency to alleviate the unwanted side effects) working
synergistically with a utrophin upregulator, has the potential to
become the new standard of care for all DMD patients.
These results show proof-of-principle for the development of
small molecules able to increase levels of utrophin for the therapy
of DMD. The great advantage of this approach is that it will be
Figure 6. Effect of SMT C1100 on in vivo parameters of
exercised mdx mice. (A) Maximal fore limb strength after 4 weeks
of either exercise and/or drug treatment. The values are mean 6 SEM
from the number of animals shown in each bar (B) Normalized force
increment, i.e. difference between the mean values of normalized fore
limb strength at time 4 and at time 0. Normalized force values have
been calculated for each mouse as the ratio of maximal fore limb
strength to mouse body weight. The values are mean 6 SE. The SE of
DNF has been calculated as detailed elsewhere [14,21]. For (A) and (B)
statistical significance between groups was evaluated by ANOVA test
for multiple comparison (F-values) and Bonferroni t-test post hoc
correction. Significantly different versus *sedentary mdx and
1Exer mdx;
p,0.05; (C) Resistance to treadmill running, calculated as the maximal
distance the mouse can run when undergoing a single bout of treadmill
exercise. The values are mean 6 SEM from 3–7 mice and show the
maximal distance run (in meters) at T0 (start of forced exercise and
dosing) and after four (T4) and five weeks (T5). Statistical significance
between groups was evaluated by ANOVA test for multiple comparison
(F-values) and Bonferroni t-test post hoc correction. Highly significant
differences were observed between groups and within groups at the
different ages (F.10; p,0.005). The symbols show statistical differenc-
es *versus sedentary mdx at T4 and #versus vehicle-treated exercised
mdx at either T4 or T5 (p,0.05 and less).
doi:10.1371/journal.pone.0019189.g006
SMT C1100 Reduces mdx Dystrophic Symptoms
PLoS ONE | www.plosone.org 8 May 2011 | Volume 6 | Issue 5 | e19189possible to treat all DMD and Becker patients, irrespective of
their dystrophin mutation. In addition, it could also be used in
combination with existing/novel strategies in the future, includ-
ing utrophin stabilisation strategies such as biglycan.
In choosing a dosing route, an orally bioavailable product to be
taken at home would be the ideal preference. In short, SMT
C1100 has the perfect profile - an oral drug suitable for treating all
DMD patients. In the recent clinical trial sponsored by BioMarin,
after repeat dosing SMT C1100 (BMN-195) achieved low plasma
exposure. This is frequently a problem in Phase I trials and issues
of low exposure can often be addressed by developing new
formulations of the drug to increase bioavailability. From the data
presented here, only modest plasma levels of around 0.5 mM SMT
C1100 maintained over several hours are sufficient to generate
enough utrophin for substantial benefit. This strongly supports the
importance of retesting new formulations of SMT C1100 in new
Phase I clinical trials with a view to progressing to DMD patient
trials.
Acknowledgments
We thank Covance for designing and conducting the safety evaluation
programme for SMT C1100. For the study on exercised mdx mice we
thank Dr. Karina Litvinova and Dr. Valeriana Sblendorio for assistance
with the physiology and in vivo experiments, respectively, Dr. Antonella
Liantonio for fura-2 microspectofluometry and Prof. Beatrice Nico for
supervision on immunofluorescence and morphological studies. We
acknowledge Charles J. Sherr, M.D., Ph.D., a Howard Hughes Medical
Institute Investigator at St. Jude Children’s Research Hospital, Memphis,
USA, who developed the retroviral vector pSRalphaMSV-CDK4-tkneo
used to generate the human DMD cell line provided by Vincent Mouly
and Gillian Butler-Browne (Institute of Myology, Paris). We further
acknowledge Prof. Steve Davies and Dr. Angela Russell (Chemistry
Research Laboratories, Oxford University) who performed the initial pilot
compound screens. We are grateful to the Medical Research Council,
Muscular Dystrophy Campaign, Muscular Dystrophy Association USA
and the Association Francaise contre les Myopathies for support of the
work in Oxford. The support of Telethon-Italy (project GGP05130) for
part of the work conducted in Bari is also gratefully acknowledged.
Author Contributions
Conceived and designed the experiments: JMT RJF KED AC RFC ADL
RS FXW. Performed the experiments: RJF ACP SES DSP FJW AL SPW
AC RFC. Analyzed the data: JMT RJF ACP SES DSP KED AC RFC
ADL RS FJW FXW. Wrote the paper: JMT RJF ADL KED. Obtained
permission to use the retroviral vector pSRalphaMSV-CDK4-tkneo used
to generate the human DMD cell line: RJF.
References
1. Bogdanovich S, Perkins KJ, Krag TO, Khurana TS (2004) Therapeutics for
Duchenne muscular dystrophy: current approaches and future directions. J Mol
Med 82: 102–15.
2. Khurana TS, Davies KE (2003) Pharmacological strategies for muscular
dystrophy. Nat Rev Drug Discov 2: 379–90.
3. McDonald CM, Henricson EK, Han JJ, Abresch RT, Nicorici A, et al. The 6-
minute walk test as a new outcome measure in Duchenne muscular dystrophy.
Muscle Nerve 41: 500–10.
4. Goemans NM, Tulinius M, Buyse G, Wilson R, de Kimpe R, et al. (2010) 24
week follow-up data from a phase I/IIa extension study of PRO051/
GSK2402968 in subjects with Duchenne muscular dystrophy. Neuromusc
Disord 20: 639.
5. Shrewsbury SB, Cirak S, Guglieri M, Bushby K, Muntoni F (2010) Current
progress and preliminary results with the systemic administration trial of AVI-
4658, a novel phosphorodiamidate morpholino oligomer (PMO) skipping
dystrophin exon 51 in Duchenne muscular dystrophy (DMD). Neuromuscular
Disorders 20: 639–640.
6. Goyenvalle A, Babbs A, Powell D, Kole R, Fletcher S, et al. (2009) Prevention of
Dystrophic Pathology in Severely Affected Dystrophin/Utrophin-deficient Mice
by Morpholino-oligomer-mediated Exon-skipping. Mol Ther 18: 198–205.
7. Beroud C, Tuffery-Giraud S, Matsuo M, Hamroun D, Humbertclaude V, et al.
(2007) Multiexon skipping leading to an artificial DMD protein lacking amino
acids from exons 45 through 55 could rescue up to 63% of patients with
Duchenne muscular dystrophy. Hum Mutat 28: 196–202.
Figure 7. Effect of SMT C1100 treatment on calcium-dependent
functional parameters of exercised mdx muscles. (A) Strength-
duration curves describing the mechanical threshold of treated and/or
untreated EDL muscle fibers. The values are means 6S.E.M. (from 10–45
fibers from 3–5 muscles) of the membrane potential at which
contraction occurs in response to a depolarizing voltage step of
variable duration (5–500 ms) by means of two microelectrode ‘‘point’’
voltage clamp method. The goodness-of-fit has been estimated by x
2
analysis. Error bars are sometime not detectable if smaller than symbol
size. Although not shown for graphical reasons, the threshold values of
C1100 treated myofibres are significantly different with respect to those
of untreated ones, at each pulse duration (0.001,p,0.05 by Student’s
t test); (B) ratio between twitch (sPtw) and tetanic tension, as mean
6S.E.M. from 5–7 EDL muscles. Significantly different *versus Exer mdx;
p,0.05 and 1versus sedentary mdx;p ,0.025.
doi:10.1371/journal.pone.0019189.g007
SMT C1100 Reduces mdx Dystrophic Symptoms
PLoS ONE | www.plosone.org 9 May 2011 | Volume 6 | Issue 5 | e191898. Amenta AR, Yilmaz A, Bogdanovich S, McKechnie BA, Abedi M, et al. (2011)
Biglycan recruits utrophin to the sarcolemma and counters dystrophic pathology
in mdx mice. Proc Natl Acad Sci U S A 108: 762–7.
9. Krag TO, Bogdanovich S, Jensen CJ, Fischer MD, Hansen-Schwartz J, et al.
(2004) Heregulin ameliorates the dystrophic phenotype in mdx mice. Proc Natl
Acad Sci U S A 101: 13856–60.
10. Peter AK, Marshall JL, Crosbie RH (2008) Sarcospan reduces dystrophic
pathology: stabilization of the utrophin-glycoprotein complex. J Cell Biol 183:
419–27.
11. Mattei E, Corbi N, Di Certo MG, Strimpakos G, Severini C, et al. (2007)
Utrophin up-regulation by an artificial transcription factor in transgenic mice.
PLoS ONE 2: e774.
12. Tinsley J, Deconinck N, Fisher R, Kahn D, Phelps S, et al. (1998) Expression of
full-length utrophin prevents muscular dystrophy in mdx mice. Nat Med 4:
1441–4.
13. Morgan JE, Beauchamp JR, Pagel CN, Peckham M, Ataliotis P, et al. (1994)
Myogenic cell lines derived from transgenic mice carrying a thermolabile T
antigen: a model system for the derivation of tissue-specific and mutation-specific
cell lines. Dev Biol 162: 486–98.
14. De Luca A, Pierno S, Liantonio A, Cetrone M, Camerino C, et al. (2003)
Enhanced dystrophic progression in mdx mice by exercise and beneficial effects
of taurine and insulin-like growth factor-1. J Pharmacol Exp Ther 304: 453–63.
15. Burdi R, Rolland JF, Fraysse B, Litvinova K, Cozzoli A, et al. (2009) Multiple
pathological events in exercised dystrophic mdx mice are targeted by
pentoxifylline: outcome of a large array of in vivo and ex vivo tests. J Appl Physiol
106: 1311–24.
16. Cooper ST, Lo HP, North KN (2003) Single section Western blot: improving
the molecular diagnosis of the muscular dystrophies. Neurology 61: 93–7.
17. Squire S, Raymackers JM, Vandebrouck C, Potter A, Tinsley J, et al. (2002)
Prevention of pathology in mdx mice by expression of utrophin: analysis using an
inducible transgenic expression system. Hum Mol Genet 11: 3333–44.
18. Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using
real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25:
402–8.
19. Hirst RC, McCullagh KJ, Davies KE (2005) Utrophin upregulation in
Duchenne muscular dystrophy. Acta Myol 24: 209–16.
20. Miura P, Jasmin BJ (2006) Utrophin upregulation for treating Duchenne or
Becker muscular dystrophy: how close are we? Trends Mol Med 12: 122–9.
21. De Luca A, Nico B, Rolland JF, Cozzoli A, Burdi R, et al. (2008) Gentamicin
treatment in exercised mdx mice: Identification of dystrophin-sensitive pathways
and evaluation of efficacy in work-loaded dystrophic muscle. Neurobiol Dis 32:
243–53.
SMT C1100 Reduces mdx Dystrophic Symptoms
PLoS ONE | www.plosone.org 10 May 2011 | Volume 6 | Issue 5 | e19189